Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia in the EU ...

The results were so strong in showing the benefit of this therapy for patient survival that we were able to stop the trial ...